These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29303937)

  • 21. Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer: A Single-center Experience.
    Bacalbasa N; Dima S; Balescu I; David L; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Jul; 35(7):4099-104. PubMed ID: 26124361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progress in preoperative evaluation methods regarding cytoreduction in patients with advanced ovarian cancer].
    Liu J; Zhang K
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):854-859. PubMed ID: 28845013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current South African clinical Practice in Debulking Surgery for Ovarian Cancer.
    Billson J; van der Merwe FH; Soeters RP
    Int J Gynecol Cancer; 2016 Oct; 26(8):1428-33. PubMed ID: 27488214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
    Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
    Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International Gynecologic Cancer Society (IGCS) 2016: Meeting report.
    Del Carmen MG; Rice LW
    Gynecol Oncol; 2017 Jan; 144(1):11-15. PubMed ID: 27847107
    [No Abstract]   [Full Text] [Related]  

  • 27. Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): a questionnaire survey.
    Barton DP; Adib T; Butler J
    Gynecol Oncol; 2013 Nov; 131(2):347-51. PubMed ID: 23954901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
    Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
    Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot of an International Collaboration to Build Capacity to Provide Gynecologic Oncology Surgery in Botswana.
    Luckett R; Kalenga K; Liu F; Esselen K; Awtrey C; Mmalane M; Moloi T; Ricciotti H; Grover S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1807-1811. PubMed ID: 30308556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies.
    Phelps DL; Saso S; Ghaem-Maghami S
    Br J Cancer; 2020 Nov; 123(10):1471-1473. PubMed ID: 32830203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovations in surgery and peri-operative care: A technical gimmick or true oncology advance?
    Fotopoulou C; Krivak TC; Chang SJ
    Gynecol Oncol; 2021 Apr; 161(1):1-3. PubMed ID: 33762085
    [No Abstract]   [Full Text] [Related]  

  • 33. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
    Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer.
    Eng OS; Raoof M; Blakely AM; Yu X; Lee SJ; Han ES; Wakabayashi MT; Yuh B; Lee B; Dellinger TH
    J Surg Oncol; 2018 Jul; 118(1):121-126. PubMed ID: 29878375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The limits of aggressive surgical cytoreduction.
    Levine DA
    Gynecol Oncol; 2018 Aug; 150(2):205-206. PubMed ID: 30025830
    [No Abstract]   [Full Text] [Related]  

  • 38. Who should operate on patients with ovarian cancer? An evidence-based review.
    Giede KC; Kieser K; Dodge J; Rosen B
    Gynecol Oncol; 2005 Nov; 99(2):447-61. PubMed ID: 16126262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.